Odevixibat after liver transplant in patients with progressive familial intrahepatic cholestasis type 1: A case series.

ABSTRACT:

Objectives

Patients with progressive familial intrahepatic cholestasis type 1 (PFIC1) who have undergone liver transplantation (LT) may have unmet needs and impacts on daily life due to post-LT complications, including diarrhea and hepatic steatosis. Here, we describe the effects of the ileal bile acid transporter inhibitor odevixibat on diarrhea and hepatic steatosis in a cohort of patients with PFIC1 post-LT.

Methods

Treating physicians from six centers retrospectively collected data through July 2023 on patients with PFIC1 who received odevixibat post-LT. Data collected included demographics, medical history, and symptom presentation, characteristics of diarrhea, and liver imaging and/or histopathology.

Results

Overall, nine male patients with PFIC1 (seven aged <18

SUBMITTER: Vogel GF 

PROVIDER: S-EPMC12666498 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature